A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study To Evaluate Efficacy And Safety Of Dcvac/Pca Versus Placebo In Men With Metastatic Castration Resistant Prostate Cancer Eligible For 1St Line Chemotherapy
Posted Date: Jul 8, 2018
- Investigator: Nagla Abdel Karim
- Specialties: Hematology/Oncology, Prostate Cancer, Oncology, Cancer
- Type of Study: Drug
The main purpose of this study is to find out if the study drug given with standard of care chemotherapy makes people with prostate cancer live longer than giving the standard of care chemotherapy and a placebo. The investigators also hope to learn about how long it takes for the tumor to progress, good and/or bad changes to pain levels and any good and/or bad changes to daily activities.
To Be Eligible For This Study, Patients Must Have Advanced Cancer Of The Prostate For Which The Doctor Has Recommended Treatment With Standard Of Care Chemotherapy (Docetaxel And Prednisone).
Sp005, Prostate, Castrate-Resistant , Cancer, Metastatic
For More Information:
Uc Cancer Institute